JACKSONVILLE, Fla.--(BUSINESS WIRE)--NovaBone Products, a leading biologics medical device company, today announces that the U.S. Patent and Trademark Office (USPTO) has issued notice of allowance for U.S. Patent application 14/194157 for its "Devices and Methods for the Regeneration of Bony Defects.”
“This important patent extends out property rights of our leading technology platform”
"This invention is a significant step forward in our collagen/bioactive glass technology platform because it demonstrates our ability to add very high loadings of bioactive glass in any collagen system regardless of the crosslinking method,” said Greg Pomrink, Vice President of Research and Development. “The net result of this development effort is a complete line of bioactive products that can be combined with bone marrow aspirate for enhanced bioactivity,” he concluded.
This is the second allowance for a collagen/bioactive glass device in less than 90 days.
“This important patent extends out property rights of our leading technology platform,” said Art Wotiz, President of NovaBone Products. “We have continued to innovate using this and other technologies to develop leading-edge, collage/bioactive glass products.”
NovaBone recently received patent issuance for the first allowance establishing intellectual property for Novabone as the only provider of bioactive glass/collagen bone grafting composites where the amount of bone healing glass exceeds 80%. “The patent and new allowance validates that NovaBone is seeking safer, more-effective solutions for surgeons by enhancing and improving our device technologies,” said Art Wotiz, President of NovaBone.
NovaBone is a privately held company based in Florida, USA since 2002. NovaBone developed the first bioactive synthetic bone graft offered to the orthopedic community and has long been at the forefront of bioactive glass bone graft devices. More recently, NovaBone established core competency in collagen devices. In total, NovaBone Products produces seven devices within the field of orthopedics and six for dental indications providing the medical community with unparalleled versatility and the widest range of choices in the bone graft device market.
A Notice of Allowance is issued after the USPTO makes a determination that claims in a patent application are deemed to represent patentable subject matter. The primary claim is a bone regenerative composition including 2-20% collagen and 80-98% bioactive glass.